astrazeneca_plaque

AstraZeneca jettisons European heart drug rights for $210m

pharmafile | July 24, 2018 | News story | Manufacturing and Production, Sales and Marketing |  AstraZeneca, Atacand, Cheplapharm, blood pressure, heart failure, pharma 

AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment Atacand (candesartan) to German pharmaceutical firm Cheplapharm Arzneimittel for $210 million.

The move to jettison European marketing efforts the ageing drug is part of AZ’s ongoing focus to streamline its portfolio and free up investment opportunities for new drugs in its key therapeutic areas. Last year, the drug and its variation, Atacand Plus, generated $300 million in global sales, with $86 million drawn from European markets.

As part of the deal, the total sum will be paid by the Anglo-Swedish firm in the form of a $200 million payment on completion of the deal – expected to close in the third quarter of this year – as well as $10 million in milestone payments, contingent on market success.  

Advertisement

Though it will lose the rights to the drug in Europe, AZ will continue to market it in the US and other non-European markets, and will also continue to manufacture and provide the drug as part of supply agreements.

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

The Gateway to Local Adoption Series

Latest content